Acute Kidney Injury Treatment Market 2034: EMA, PDMA, FDA Approvals, Medication, Clinical Trials, Pipeline, Prevalence, MOA, ROA and Companies by DelveInsight

Acute Kidney Injury companies are Renibus Therapeutics, Ocelot Bio, Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.
(Albany, USA) DelveInsight's "Acute Kidney Injury Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Acute Kidney Injury, historical and forecasted epidemiology as well as the Acute Kidney Injury market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Acute Kidney Injury market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Acute Kidney Injury market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Acute Kidney Injury treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Acute Kidney Injury market.

Request for a Free Sample Report @ Acute Kidney Injury Market Forecast [https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Acute Kidney Injury Market Report are:

* According to DelveInsight, Acute Kidney Injury market size is expected to grow at a decent CAGR by 2034.
* Acute Kidney Injury Market Size in the 7MM was ~USD 6,230 million in 2022 and is projected to grow during the forecast period (2024-2034).
* Leading Acute Kidney Injury companies working in the market are Renibus Therapeutics, Ocelot Bio, Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.
* Key Acute Kidney Injury Therapies expected to launch in the market are RBT-1, OCE-205, and others.
* In February 2024, CalciMedica, Inc.,a clinical-stage biopharmaceutical company, had received FDA clearance for its Investigational New Drug (IND) application for Auxora, a small molecule inhibitor targeting Orai1-containing CRAC channels. The company plans to evaluate Auxora in a Phase 2 trial, named KOURAGE, for acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). The trial is expected to begin in the first half of 2024, with data anticipated in 2025.
* In December of 2023, SeaStar Medical commenced patient enrollment in the NEUTRALIZE-Acute Kidney Injury pivotal clinical trial for its Selective Cytopheretic Device (SCD) extracorporeal therapy. This trial focuses on critically ill adults experiencing Acute Kidney Injury and necessitating continuous kidney replacement therapy (CKRT).
* In October 2023, Renibus Therapeutics marked a milestone as the first patient received a dose in the pivotal Phase III PROTECT trial for RBT-1. This trial targets patients facing post-operative complications following cardiac surgery. The company expects to unveil top-line results around mid-2025, with plans for NDA filing anticipated by early 2026.

Acute Kidney Injury Overview

Acute Kidney Injury (AKI) is a sudden decline in kidney function, leading to impaired waste elimination, electrolyte imbalances, and fluid overload. It is commonly caused by decreased blood flow to the kidneys (prerenal AKI), direct kidney damage (intrinsic AKI), or obstruction of urine flow (postrenal AKI). Common Acute Kidney Injury risk factors include dehydration, sepsis, nephrotoxic drugs (NSAIDs, aminoglycosides, contrast agents), chronic kidney disease (CKD), diabetes, and hypertension.

Acute Kidney Injury is typically diagnosed through a rise in serum creatinine, reduced urine output, and blood urea nitrogen (BUN) levels. Acute Kidney Injury Symptoms may include fatigue, swelling (edema), confusion, nausea, and shortness of breath. Severe cases can lead to metabolic acidosis, hyperkalemia, and life-threatening complications.

Acute Kidney Injury Management focuses on treating the underlying cause, optimizing fluid balance, avoiding nephrotoxic agents, and supportive care. In severe cases, dialysis may be required. Acute Kidney Injury Preventive strategies include adequate hydration, monitoring high-risk patients, and adjusting drug dosages for renal function.

Early detection and intervention are crucial for preventing Acute Kidney Injury progression and reducing the risk of chronic kidney disease (CKD) or end-stage renal disease (ESRD). Healthcare professionals should monitor kidney function in hospitalized and critically ill patients to improve outcomes.

Learn more about Acute Kidney Injury treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Acute Kidney Injury Treatment Market [https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Acute Kidney Injury Market

The Acute Kidney Injury market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Acute Kidney Injury market trends by analyzing the impact of current Acute Kidney Injury therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Acute Kidney Injury market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Acute Kidney Injury market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Acute Kidney Injury market in 7MM is expected to witness a major change in the study period 2020-2034.

Acute Kidney Injury Epidemiology

The Acute Kidney Injury epidemiology section provides insights into the historical and current Acute Kidney Injury patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Acute Kidney Injury market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Acute Kidney Injury Epidemiology @ Acute Kidney Injury Market Dynamics [https://www.delveinsight.com/report-store/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Acute Kidney Injury Drugs Uptake

This section focuses on the uptake rate of the potential Acute Kidney Injury drugs recently launched in the Acute Kidney Injury market or expected to be launched in 2020-2034. The analysis covers the Acute Kidney Injury market uptake by drugs, patient uptake by therapies, and sales of each drug.

Acute Kidney Injury Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Acute Kidney Injury market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Acute Kidney Injury Pipeline Development Activities

The Acute Kidney Injury report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Acute Kidney Injury key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Acute Kidney Injury pipeline development activities @ Acute Kidney Injury Drugs Market [https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Acute Kidney Injury Therapeutics Assessment

Major key companies are working proactively in the Acute Kidney Injury Therapeutics market to develop novel therapies which will drive the Acute Kidney Injury treatment markets in the upcoming years are Renibus Therapeutics, Ocelot Bio, Atox Bio, AM-Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, and others.

Learn more about the emerging Acute Kidney Injury therapies & key companies @ Acute Kidney Injury Clinical Trials and Advancements [https://www.delveinsight.com/sample-request/acute-kidney-injury-aki-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Acute Kidney Injury Report Key Insights

1. Acute Kidney Injury Patient Population

2. Acute Kidney Injury Market Size and Trends

3. Key Cross Competition in the Acute Kidney Injury Market

4. Acute Kidney Injury Market Dynamics (Key Drivers and Barriers)

5. Acute Kidney Injury Market Opportunities

6. Acute Kidney Injury Therapeutic Approaches

7. Acute Kidney Injury Pipeline Analysis

8. Acute Kidney Injury Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Acute Kidney Injury Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Acute Kidney Injury Competitive Intelligence Analysis

4. Acute Kidney Injury Market Overview at a Glance

5. Acute Kidney Injury Disease Background and Overview

6. Acute Kidney Injury Patient Journey

7. Acute Kidney Injury Epidemiology and Patient Population

8. Acute Kidney Injury Treatment Algorithm, Current Treatment, and Medical Practices

9. Acute Kidney Injury Unmet Needs

10. Key Endpoints of Acute Kidney Injury Treatment

11. Acute Kidney Injury Marketed Products

12. Acute Kidney Injury Emerging Therapies

13. Acute Kidney Injury Seven Major Market Analysis

14. Attribute Analysis

15. Acute Kidney Injury Market Outlook (7 major markets)

16. Acute Kidney Injury Access and Reimbursement Overview

17. KOL Views on the Acute Kidney Injury Market

18. Acute Kidney Injury Market Drivers

19. Acute Kidney Injury Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=acute-kidney-injury-treatment-market-2034-ema-pdma-fda-approvals-medication-clinical-trials-pipeline-prevalence-moa-roa-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.